https://doi.org/10.4081/reumatismo.2021.1406
Subclinical TRAPS treated with canakinumab
Submitted: 13 February 2021
Accepted: 13 June 2021
Published: 3 August 2021
Accepted: 13 June 2021
Abstract Views: 2561
PDF: 508
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Tumor necrosis factor receptor–associated periodic syndrome (TRAPS) is a rare autoinflammatory disease characterized by recurrent episodes of fever and systemic inflammation. We describe the case of a 19-year-old patient who was referred to our attention with frequent subclinical TRAPS episodes characterized by mild arthralgias and crampy abdominal pain, without fever. Inflammatory markers, including serum amyloid A which increases the risk of long-term amyloidosis, were persistently high also when the patient was in good general conditions. Therapy with human anti-interleukin 1β monoclonal antibody, canakinumab, led to disease control and normalization of the inflammatory markers, which are currently still normal. This clinical case supports the need to treat also subclinical TRAPS. In this respect, canakinumab is effective and reduces the risk of developing amyloidosis.
Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol. 2017; 31: 596-609.
DOI: https://doi.org/10.1016/j.berh.2017.12.001
Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014; 73: 2160-7.
DOI: https://doi.org/10.1136/annrheumdis-2013-204184
Gattorno M, Hofer M, Federici S, et al. Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO). Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019; 78: 1025-1032.
DOI: https://doi.org/10.1136/annrheumdis-2019-215048
Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017; 76: 173-178.
DOI: https://doi.org/10.1136/annrheumdis-2015-209031
De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018; 378: 1908-1919.
DOI: https://doi.org/10.1056/NEJMoa1706314
Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011; 63: 314-24.
DOI: https://doi.org/10.1002/art.30105
Miyamae T, Hanaya A, Kawamoto M, et al. Diagnostic rate of autoinflammatory diseases evaluated by fever patterns in pediatric- and adult-onset patients. J Clin Rheumatol. 2020; 26: 60-62.
DOI: https://doi.org/10.1097/RHU.0000000000000929
Procopio V, Manti S, Bianco G, et al. Genotype-phenotype correlation in FMF patients: A "non classic" recessive autosomal or "atypical" dominant autosomal inheritance?. Gene. 2018; 641: 279-286.
DOI: https://doi.org/10.1016/j.gene.2017.10.068
Quillinan N, Mohammad A, Mannion G, et al. Imaging evidence for persistent subclinical fasciitis and arthritis in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) between febrile attacks. Ann Rheum Dis. 2010; 69: 1408-9.
DOI: https://doi.org/10.1136/ard.2009.118661
Kallinich T, Haffner D, Rudolph B, et al. "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis. 2006; 65: 958-60.
DOI: https://doi.org/10.1136/ard.2005.043570
Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol. 2004; 31: 2519-22.
DOI: https://doi.org/10.1055/s-2003-45080
Scarpioni R, Ricardi M, Albertazzi V. Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. World J Nephrol. 2016; 5: 66-75.
DOI: https://doi.org/10.5527/wjn.v5.i1.66
How to Cite
Amatruda, M., Carucci, N., Fede, C., & Conti, G. (2021). Subclinical TRAPS treated with canakinumab. Reumatismo, 73(2), 131–134. https://doi.org/10.4081/reumatismo.2021.1406
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- J.Ch Gerster, Amyloidoses as seen by the Rheumatologist , Reumatismo: Vol. 53 No. 3 (2001)
- A. Icardi, P. Araghi, M. Ciabattoni, U. Romano, P. Lazzarini, G. Bianchi, Kidney involvement in rheumatoid arthritis , Reumatismo: Vol. 55 No. 2 (2003)
- S. Bellissimo, M.G. Ferrucci, A. Gallo, S. Stisi, Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis , Reumatismo: Vol. 59 No. 3 (2007)
- F. Carubbi, A. Alunno, R. Gerli, R. Giacomelli, Histopathology of salivary glands , Reumatismo: Vol. 70 No. 3 (2018): Monographic issue on Histopathology in Rheumatic Diseases
- V. Bruzzese, P. Scolieri, J. Pepe, Biclonal gammopathy of undetermined significance in a patient with systemic lupus erythematosus and antiphospholipid syndrome , Reumatismo: Vol. 73 No. 4 (2021)
- Leonardo Punzi, Mauro Galeazzi, Vittorio Modena, Stefano Bombardieri, The registry for the systemic autoinflammatory syndromes of the Italian Society of Rheumatology , Reumatismo: Vol. 58 No. 1 (2006)
- R. Scolozzi, A. Boccafogli, L. Vicentini, Hyper-IgD syndrome and hereditary periodic fever syndromes , Reumatismo: Vol. 56 No. 3 (2004)
- M. Benucci, F. Li Gobbi, A. Del Rosso, G. Gambacorta, A. Mannoni, Association between Serum Amiloid A (SAA) in salivary glands and high levels of circulating β2-microglobulin in patients with Sjögren syndrome , Reumatismo: Vol. 55 No. 2 (2003)
- A. Leone, R. Manna, E. Verrecchia, M. Cipullo, D. Rigante, Long-term treatment with anakinra and canakinumab resolves patellar subchondral erosion in neonatal-onset multisystem inflammatory disease , Reumatismo: Vol. 71 No. 1 (2019)
- T. Borges, A. Barbosa, S. Silva, Adult-onset systemic autoinflammatory disorders: a clinical approach , Reumatismo: Vol. 71 No. 4 (2019)
You may also start an advanced similarity search for this article.
